Uproleselan + chemotherapy did not outperform chemotherapy alone for relapsed or refractory AML; but authors saw interesting trends in subgroups.
Daratumumab reduced progression to multiple myeloma and prolonged overall survival in patients with high-risk smouldering MM.
The investigational therapy GLPG5101 was associated with high response and a favourable safety profile in relapsed or refractory non-Hodgkin lymphoma.
Rilzabrutinib improved efficacy and QoL outcomes over placebo with a favourable safety profile among heavily pre-treated adults with immune thrombocytopenia.
Revumenib continued to display promising anti-tumour activity among patients with relapsed or refractory KMT2Ar acute leukaemia.
Hydroxyurea was associated to a reduction in clinical adverse events and improvements in haematological parameters in the phase 2 PIVOT trial.
Daratumumab plus VRd outperformed VRd alone in MRD-negativity rates for previously untreated multiple myeloma cases ineligible for transplant.
Adding blinatumomab to standard chemotherapy improved survival in paediatric patients with NCI standard-risk B-ALL at average or high relapse risk.
The French health authority updated its recommendations for improving HIV prevention and treatment. Here´s an overview of the main points.
Despite the decline in new HIV infections in recent decades, UNICEF is concerned about the gender gap in HIV prevalence.
The 66th Annual Meeting of the American Society of Hematology this December is a crucial forum on the latest advances in haematology.
Artificial intelligence is revolutionising cancer diagnosis, as the Institut Curie steps up its collaboration with Ibex Medical Analytics for post-stroke cancers.
New research shows that RA increases the risk of cognitive impairment. Those affected particularly show deficits in memory and executive functions.
For many, a plant-based diet equals health. But is this always so? One study examined ultra-processed, purely plant-based foods' effects on the heart.
Glioblastoma is an extremely aggressive brain tumour, despite various therapeutic approaches, with a mostly poor prognosis. Which treatment is recommended?
Recent advances in melanoma diagnosis and treatment emphasise the importance of new biomarkers for early detection and innovative therapies for advanced melanoma.
Tamuzimod improved clinical, endoscopic, and histologic outcomes compared with placebo in moderately to severely active UC at week 52.
Upadacitinib induction and maintenance therapy were associated with higher rates of normalisation of health-related quality-of-life (HRQoL) than placebo.
Tulisokibart displayed durable improvements in clinical and endoscopic outcomes in patients with moderately to severely active ulcerative colitis.
Perianal fistulising Crohn’s disease was associated with increased IFN-γ expression and response in fistula tracts and luminal mucosa.